icon
icon
icon
icon
Upgrade
icon

Monogram Technologies: Navigating FDA Response for mBôs TKA System

AInvestWednesday, Oct 2, 2024 6:05 pm ET
1min read
Monogram Technologies Inc. (NASDAQ: MGRM) recently received an Additional Information Request (AIR) from the U.S. Food and Drug Administration (FDA) regarding its 510(k) premarket filing submission for the mBôs TKA System. The AIR has placed the Application on hold, requiring the company to provide a complete response within 180 days to avoid withdrawal.


The FDA's response has significant implications for Monogram's clinical trial plans and FDA clearance timeline. The 180-day deadline forces the company to prioritize addressing the AIR while maintaining progress on its clinical trials. Monogram aims to obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals in early Q1 2025 and seek clearance for the mBôs TKA System. The company also plans to continue exploring domestic and international relationships.

The specific information requested in the AIR remains unclear, but it may impact the design or functionality of the mBôs TKA System. Monogram will need to analyze the AIR and determine the necessary adjustments to address the FDA's concerns. The company's ability to adapt and respond to the AIR will be crucial in obtaining FDA clearance and commercializing the mBôs TKA System.


The FDA's feedback on the suitability of Indian clinical data influences Monogram's strategy for obtaining FDA clearance. The company is pursuing a submission for its active modality with Outside the United States (OUS) clinical data in parallel with addressing the AIR for its semi-active system. Monogram believes that the increased clarity regarding the potential suitability of Indian clinical data is de-risking the process.

The FDA's response to the AIR may impact investor confidence in Monogram Technologies' stock and future growth prospects. Investors will closely monitor the company's progress in addressing the AIR and its impact on the FDA clearance timeline. A successful response to the AIR and timely FDA clearance could boost investor confidence, while delays or setbacks may lead to uncertainty.

In conclusion, Monogram Technologies faces a critical 180-day deadline to address the FDA's AIR and maintain its clinical trial plans. The company's ability to navigate this challenge and adapt to the FDA's requirements will be crucial in obtaining FDA clearance and commercializing the mBôs TKA System. Investors will closely watch Monogram's progress as it works towards regulatory approval and growth.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.